U.S. Food and Drug Administration Approves KALYDECOâ„¢ (ivacaftor) for Use in Eight Additional Mutations that Cause Cystic Fibrosis

[Business Wire] – Vertex Pharmaceuticals Incorporated today announced the U.S. Food and Drug Administration approved a supplemental New Drug Application for KALYDECOTM for people with cystic fibrosis ages 6 and older who have one of eight additional muta more

View todays social media effects on VRTX

View the latest stocks trending across Twitter. Click to view dashboard

See who Vertex is hiring next, click here to view